Cruz D N
Section of Nephrology, Department of Medicine, Yale University School of Medicine, 333 Cedar Street LMP 2071, New Haven, CT 06520-8029, USA.
Expert Opin Pharmacother. 2000 May;1(4):835-40. doi: 10.1517/14656566.1.4.835.
Midodrine is an oral agent which acts as a selective peripherally-acting alpha-receptor agonist. Midodrine is a prodrug that is almost completely absorbed after oral administration and converted into its active drug de-glymidodrine in the systematic circulation, with a bioavailability of 93%. It has been used successfully in the treatment of neurogenic orthostatic hypotension and more recently, in the treatment of dialysis hypotension. It acts through vasoconstriction of the arterioles and the venous capacitance vessels, thereby increasing peripheral vascular resistance and augmenting venous return, respectively. It is a unique agent in the armamentarium against orthostatic hypotension since it has minimal cardiac and CNS effects. This article will review the literature on midodrine for conditions of autonomic dysfunction, with focus on recent studies on its use in haemodialysis patients.
米多君是一种口服药物,作为一种选择性外周作用的α受体激动剂。米多君是一种前体药物,口服给药后几乎完全吸收,并在体循环中转化为其活性药物去甘氨酸米多君,生物利用度为93%。它已成功用于治疗神经源性直立性低血压,最近还用于治疗透析性低血压。它通过使小动脉和静脉容量血管收缩起作用,从而分别增加外周血管阻力和增强静脉回流。它是治疗直立性低血压药物中的一种独特药物,因为它对心脏和中枢神经系统的影响极小。本文将综述关于米多君治疗自主神经功能障碍的文献,重点关注其在血液透析患者中应用的近期研究。